Exhale (R) Stent for Emphysema

NCT ID: NCT00207337

Last Updated: 2008-01-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-07-31
• Study Completion Date: 2006-05-31

Brief Summary

Current treatment for emphysema is limited to measures that include inhaled oxygen, bronchodilators, anti-inflammatory drugs and pulmonary rehabilitation. Highly invasive procedures such as lung volume reduction surgery or lung transplantation are also performed. Treatment using the Exhale Drug-Eluting Stent (DES) is a minimally invasive bronchoscopic treatment that has the potential to reduce shortness of breath in emphysema patients. This study tests the safety and effects of Exhale DES in the treatment of patients with emphysema.

Detailed Description

Emphysema affects an estimated 60 million people worldwide and is a major cause of morbidity and mortality. In its most basic terms, emphysema causes the destruction of lung parenchyma resulting in collateral ventilation from one part of the lung to another through the disrupted alveolar walls, to the point that gas transport from one part of the lung to another may exceed gas flow through the small airways. In other words, the gas can move freely about within the lung, but it cannot get out, which causes over inflation, or hyperinflation of the diseased lung. When the disease is far advanced, patients are afflicted with disabling dyspnea that progressively restricts their activities and eventually causes great suffering. The crippling effects of end-stage emphysema, including severe dyspnea and marked limitation of activities, relate in large measure to the dynamic hyperinflation of the lungs associated with the loss of elasticity, gas trapping and collapse of small airways. The progressive enlargement of the thorax and flattening of the diaphragm render inspiratory muscles inefficient, increase the work of breathing and contribute to a feeling of breathlessness. The major medical therapeutic modalities include bronchodilator and anti-inflammatory drugs directed at decreasing airway resistance and antibiotics to combat infection. Pulmonary rehabilitation techniques and exercise training have proven of palliative benefit. In general, the results of medical treatment for advanced airway obstruction frequently result in a persistently anguished patient and frustrated physician. A system that could efficiently decompress emphysematous lungs with each breath would result in significant clinical benefit, including lessened dyspnea, decreased work of breathing, and increased exercise tolerance.

In addition to medical therapies, there are two surgical therapies available to emphysema sufferers: Lung transplantation and Lung Volume Reduction Surgery (LVRS). In the National Emphysema Treatment Trial (NETT), LVRS was shown to be effective in a sub-set of emphysema patients, but it had the drawback of increased short-term mortality as compared to the medical control arm. This was likely due to the invasiveness of LVRS.

Lung transplantation is a widely accepted surgical treatment for emphysema; however it is an unrealistic option for most patients. The selection criteria are very stringent for acceptance to receive a donor lung(s). Lung transplantation carries a high long-term morbidity and mortality and is severely limited by the shortage of available donor lungs.

We seek to take advantage of collateral ventilation seen in advanced emphysema by creating passageways from the lung parenchyma to large airways, through which air can escape the lungs during exhalation. The Exhale therapeutic intervention should be applicable to the majority of emphysema patients who suffer from hyperinflation of their lungs. It would be desirable to have a therapeutic option that is both less invasive and more readily available to emphysema sufferers. We have been working on such a therapy and have begun to investigate it in the clinic.

Conditions

Emphysema

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Exhale Drug-Eluting Stent

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. High resolution computed tomography (CT) scan evidence of bilateral emphysema

2. Residual volume (RV) ≥ 220% predicted.

3. Total lung capacity (TLC) ≥ 133% of predicted value.

4. Forced expiratory volume (FEV1) < 40% of predicted or FEV1 < 1 liter.

5. Marked dyspnea, scoring ≥ 2 on the modified Medical Research Council scale of 0-4.

6. Patient has undergone pulmonary rehabilitation of 16 - 20 sessions.

Exclusion Criteria

1. FEV1 > 20%

2. Diffusing capacity for carbon monoxide (DLco) < 15% of predicted.

3. Respiratory infection requiring > 3 hospitalizations in past year

4. Inability to walk > 140 meters in 6 minutes

5. Giant bulla > 1/3 of one lung's volume

6. Previous lung volume reduction surgery (LVRS) or lobectomy.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Broncus Technologies

INDUSTRY

Sponsor Role: lead

Principal Investigators

Gregory I. Snell, MD

Role: PRINCIPAL_INVESTIGATOR

The Alfred

Locations

The Prince Charles Hospital

Rode Road, Chermside, Queensland, Australia

The Alfred Hospital

Prahran, Victoria, Australia

Concord Repatriation General Hospital

Burwood, , Australia

Irmandade Santa Casa de Misericordia

Porto Alegre, , Brazil

Universitätsklinik des Saarlandes

Homburg, Saarland, Germany

Medizinische Hochschule Hannover

Hanover, , Germany

Countries

Australia; Brazil; Germany

Related Links

http://www.broncus.com

Broncus Technologies, Inc corporate web page

http://www.lungusa.org

American Lung Association

Other Identifiers

0304-28

Identifier Type: -

Identifier Source: org_study_id